News

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach

Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday. The company posted quarterly losses of 90 cents per share which missed the analyst consensus estimate of losses of 87 cents per share. The company reported quarterly sales of $15.600 million which missed the analyst consensus estimate of $18.097 million. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) announced that it is entering an exclusive global licensing agreement with Arvinas and Pfizer Inc. (NYSE:PFE) for its

On Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous

PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.

These stocks are facing some headwinds, but they may prove to be big winners in the long run.

Pfizer (NYSE:PFE) and Arvinas have transferred global development and commercialization rights for VEPPANU (vepdegestrant) to Rigel Pharmaceuticals. VEPPANU is the first FDA approved PROTAC therapy and was recently cleared in the U.S. for certain patients with advanced breast cancer. The global license agreement makes Rigel the commercial leader for VEPPANU, while Pfizer and Arvinas retain an economic interest through the deal structure. For investors watching NYSE:PFE, this move highlights...

It's a great time to "buy low."

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

The Dow Jones Industrial Average would be even higher if it had more exposure to energy stocks.

Warren Buffett built Berkshire Hathaway by paying reasonable prices for durable cash flows, and three of his current bets still trade below $30 a share. With Greg Abel sitting on a record cash pile, the sub-$30 aisle is where value hunters are scanning for the kind of brand-heavy, cash-generative franchises Omaha tends to favor when ... 3 Berkshire Stocks Under $30 and 2 Under $30 Greg Abel May Buy

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.

Can a push into oncology and next-generation therapies make up for Pfizer's post-Covid letdown?

The market seemed underwhelmed by last week's earnings announcement from Pfizer Inc. ( NYSE:PFE ) despite the healthy...

At 6.7%, Pfizer's dividend yield is exceptionally high, but whether it's sustainable is debatable.

As federal policy chills domestic demand, some companies are increasingly leaning on sales from international markets.

Pfizer's acquired and recently launched products generated strong growth last quarter.

In early May 2026, Novavax reported first-quarter revenue of US$139.51 million versus US$666.66 million a year earlier, swinging from net income of US$518.65 million to a net loss of US$9.49 million and posting basic and diluted loss per share of US$0.06 from continuing operations. Despite the year-on-year drop in sales and profitability, Novavax’s quarterly results exceeded market expectations and were underpinned by new Matrix-M licensing activity, including an upfront US$30 million...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer. The rally is outpacing fellow vaccine names Pfizer (NYSE:PFE), up 2% near $26.10, and Novavax (NASDAQ:NVAX), basically flat ... Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly’s Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Pfizer (NYSE:PFE) received FDA approval for VEPPANU (vepdegestrant), the first PROteolysis TArgeting Chimera, or PROTAC, therapy for certain patients with endocrine-resistant advanced breast cancer. Positive Phase 3 data for ELREXFIO in relapsed or refractory multiple myeloma were reported, supporting potential expanded use in this blood cancer setting. Settlements with generic manufacturers extended U.S. patent protection for VYNDAMAX to 2031, affecting a key cardiology franchise. For...

Pfizer is an innovative pharmaceutical giant that investors have given up on, which is an opportunity if you think long-term.

Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to invest in according to hedge funds. On May 5, Pfizer reported a strong start to 2026, achieving Q1 revenues of $14.5 billion, which represents a 2% operational increase compared to the prior-year period. This growth was driven by a 22% operational revenue surge […]

If you are trying to generate income in retirement, these three high-yield healthcare stocks could be the perfect fit for you.

BMO Capital Markets Managing Director, BioPharma Equity Research Evan Seigerman joins Julie Hyman on Market Catalyst to discuss the battle for GLP-1 dominance between Novo Nordisk (NVO) and Eli Lilly (LLY).

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.

Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.

Is Pfizer a yield trap? No way.